| __timestamp | Exelixis, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 1643000000 |
| Thursday, January 1, 2015 | 57305000 | 1532000000 |
| Friday, January 1, 2016 | 116145000 | 1364000000 |
| Sunday, January 1, 2017 | 159362000 | 1334000000 |
| Monday, January 1, 2018 | 206366000 | 1484000000 |
| Tuesday, January 1, 2019 | 228244000 | 1638000000 |
| Wednesday, January 1, 2020 | 293355000 | 1726000000 |
| Friday, January 1, 2021 | 401715000 | 2001000000 |
| Saturday, January 1, 2022 | 459856000 | 2009000000 |
| Sunday, January 1, 2023 | 542705000 | 2151000000 |
| Monday, January 1, 2024 | 492128000 | 2318000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic growth. Over the past decade, Zoetis Inc. and Exelixis, Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Zoetis Inc. consistently allocated a significant portion of its budget to SG&A, with a peak in 2023, reaching approximately 2.15 billion USD. This represents a steady increase of about 31% from 2014. In contrast, Exelixis, Inc. exhibited a more aggressive growth in SG&A spending, skyrocketing by over 900% during the same period, culminating in 2023 with expenses around 543 million USD. This divergence highlights Zoetis's stable investment strategy versus Exelixis's rapid expansion approach, reflecting their unique market strategies and growth trajectories.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Exelixis, Inc.
Selling, General, and Administrative Costs: Novartis AG vs Zoetis Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Comparing SG&A Expenses: Zoetis Inc. vs Lantheus Holdings, Inc. Trends and Insights
Selling, General, and Administrative Costs: Zoetis Inc. vs MorphoSys AG
Breaking Down SG&A Expenses: Zoetis Inc. vs Celldex Therapeutics, Inc.
Insmed Incorporated or Exelixis, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Apellis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Supernus Pharmaceuticals, Inc.